SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors debate the potential for a transformative buyout following reports of massive pharmaceutical M&A activity in the oncology space. Community discussions are highly polarized, with bulls highlighting the trial's prolonged survival timeline as evidence of therapeutic success, while bears express concern over the company's financial structure and the potential for a binary clinical outcome.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating intense community speculation as investors anticipate imminent Phase 3 VELA data, fueling intense M&A discussions and optimism that sonelokimab will emerge as a best-in-class treatment for hidradenitis suppurativa. The community is closely watching for a potential data release to coincide with upcoming investor presentations, which many believe could trigger a massive rerating event due to the drug's demonstrated efficacy and superior safety profile over existing competition.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is experiencing a massive, sentiment-driven rally fueled by severe NAND flash and SSD shortages, prompting intense community debate over whether the stock is in a sustainable super-cycle or a speculative bubble. Investors are closely monitoring the stock's parabolic climb and frequent new highs, with much of the discussion focused on the potential for continued momentum into upcoming earnings and the high stakes for those currently holding short positions.

Roundhill ETF Trust - Roundhill Memory ETF

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda, which confirms that another major OEM has validated the company's solid-state battery technology after rigorous testing. The community is actively debating the significance of this partnership, weighing the long-term potential of the technology against frustrations over the lack of immediate commercial-scale revenue.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is trending as investors focus on its role in the AI-driven energy infrastructure sector, with community excitement fueled by the company's recent purchase orders from Frontier Power USA and ongoing developments in zinc-based long-duration energy storage. Bullish sentiment is heavily influenced by the belief that Eos provides a critical solution to power grid bottlenecks required by data centers, leading to active discussions regarding the stock's potential as a multi-year growth opportunity amidst increasing sector-wide demand for reliable, non-flammable energy storage.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth Inc. is currently a focal point for investors as the company navigates strategic expansion efforts and secures federal funding to build out a domestic rare earth supply chain. Market sentiment is heavily influenced by the firm's central role in critical mineral security and ongoing discussions regarding its competitive positioning in the rare earth sector.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting intense investor attention following a significant clinical data release for Lupkynis and increased share accumulation by CEO Kevin Tang. While the community is actively debating the potential for an imminent buyout or strategic acquisition, sentiment remains divided between hopeful longs anticipating a catalyst-driven surge and skeptics frustrated by a lack of direct management communication.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is experiencing significant volatility and social media attention following an announcement regarding a co-development deal with Midjourney, which investors are analyzing as a potential long-term catalyst for the company's semiconductor-based ultrasound technology. While bulls highlight institutional backing and the transformative potential of AI in medical imaging, bears are actively debating the high valuation, persistent cash burn, and the risk of a share offering following the rapid price move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

Satsuma Pharmaceuticals Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

STSASatsuma Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest STSA News